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Introduction
The advent of immunotherapy dramatically changed 
the therapeutic landscape of non-oncogene addicted 
metastatic non-small cell lung cancer (NSCLC). In the 
last few years, check-point inhibitors (CPIs) targeting 
the programmed cell death-1 (PD-1)/programmed death 
ligand-1 (PD-L1) axis, have shown a significant superiority 
over chemotherapy, in terms of efficacy and tolerability, 
improving disease control, overall survival (OS) and quality 
of life (QoL), both in first- and second-line setting (1-7). 
Based on the Check-Mate 017/057 and OAK clinical trials’ 
results, nivolumab and atezolizumab entered in the clinical 
practice for the second/third-line treatment of PD-L1 
unselected NSCLC patients, while the KEYNOTE-010 
and 024 studies granted Pembrolizumab approval as new 
standard of care for both pre-treated and untreated NSCLC 
patients with tumor PD-L1 expression of at least 1% and 
50%, respectively. The introduction of immunotherapy into 
clinical practice produced a significant increase of long-
term survival, reaching 16% at 5 years in pre-treated, PD-
L1 unselected population, and about 30% when considering 
naïve patients with high PD-L1 expression, as compared 
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to 5.5% in the chemotherapy era (8). More recently, the 
combination of Pembrolizumab with first-line platinum-
based chemotherapy resulted in a significant increase 
of tumor responses and survival outcomes compared to 
chemotherapy alone (9-11), regardless of tumor histology 
and PD-L1 expression levels, thus emerging as an additional 
effective option for the treatment of non-oncogene 
addicted, metastatic NSCLC. Together with the great 
efficacy, CPIs are characterized by an optimal tolerability 
profile, thus allowing their administration for prolonged 
periods. However, these drugs are not free of side effects, 
mostly due to the abnormal activation of the immune 
system. In fact, it is estimated that about 70% of patients 
develop adverse events during the course of CPIs therapy, 
usually not disabling and well manageable with medical 
therapy or drug withdrawal (12). Considering that the 
majority of available evidence is limited to highly selected 
population which reflects the ones included into clinical 
trials, few data are available from the real-life setting. Some 
clinical series have recently confirmed an optimal efficacy 
and tolerability of CPIs in special subgroups of patients, 
like elderly (13), poor performance status (14), and brain 
metastasis (15), who are quite common in the real-word 
scenario. Conversely, the potential activity and safety profile 
of CPIs in NSCLC patients who received a concomitant use 
of steroids or were previously diagnosed with autoimmune 
disease (AID) remains still controversial. In this review 
we provided an updated literature overview, summarizing 
available evidence and reporting practical suggestions, 
which may guide physicians in their current practice. 
Concomitant use of steroids
Clinical evidences
Glucocorticoids are widely used for the clinical management 
of advanced NSCLC patients to treat both cancer-related 
and cancer unrelated symptoms (16-20). The most common 
cancer-related palliative indications include dyspnea, fatigue, 
anorexia, pain and symptomatic brain metastases. Otherwise 
patients could require steroids therapy administration for 
the clinical management of a wide range of conditions, like 
AID, chronic obstructive pulmonary disease (COPD) flare, 
prophylaxis of hypersensitivity reactions, and non-cancer 
pain. 
Steroids exert their dose-dependent immunosuppressive 
effects both on innate and adaptive immunity. Well-
established effects include the induction of T cell apoptosis 
and the maturation impairment of dendritic cells (DCs) (21). 
Moreover, some pre-clinical works demonstrated that low 
dose glucocorticoids administration is sufficient to suppress 
response to cancer immunotherapy (22). The raising concern 
on the immunosuppressive effect of glucocorticoids have 
led to a formal exclusion of patients receiving >10 mg/day 
of prednisone or its equivalent, from the majority of CPIs-
based randomized clinical trials (23). 
Different publications have clearly suggested that a short 
course of glucocorticoids therapy does not significantly 
affect T-cells activity (24,25). As a matter of fact, some 
retrospective studies showed that a transient use of 
steroids for the clinical management of immune-related 
adverse events (irAEs) do not compromise the efficacy of 
immunotherapy (26-31). Similarly, the use of steroids-based 
premedication in the record trials of recently approved 
chemo-immunotherapy combination regimens did not have 
any influence on patients’ survival outcomes (9-11). 
Conversely, the potential effect of a concomitant 
administration of steroids at the time of CPIs initiation 
in cancer patients remains still controversial. Several 
retrospective studies and case series were carried out with 
the intent to clarify the potential clinical implications of 
concomitant use of steroids in CPIs-treated, advanced 
NSCLC patients (Table 1).
Arbour et al. analyzed 640 patients who were treated 
with anti-PD-1/PD-L1 agents coming from the Memorial 
Sloan Kettering Cancer Centre (MSKCC; 455) and the 
Gustave Roussy Cancer Centre (GRCC; 185). In this study, 
90 patients (14%) were treated with a baseline >10 mg-dose 
of prednisone at the time of CPIs beginning, and treatment 
outcomes, including objective response rate (ORR), 
progression free survival (PFS), and OS, were analyzed. 
Main factors considered in the multivariate analysis 
included smoking status, Easter Cooperative Oncology 
Group performance status (ECOG-PS) and the presence of 
brain metastases. The pooled analysis showed that ≥10 mg-
prednisone administration at early stages of CPIs’ therapy 
was significantly associated to poor survival outcomes, 
specifically in terms of PFS (HR 1.31, P<0.03), and OS (HR 
1.66, P<0.001). A detrimental effect of steroids on CPIs’ 
efficacy has been observed in patients receiving ≥10 vs. 
<10 mg prednisone (32).
In a second retrospective study, Scott et al. analyzed 210 
NSCLC patients treated with nivolumab at the Cleveland 
Clinic, with 66 (31%) receiving a concomitant steroids 
therapy. The median OS of patients subjected to steroids 
treatment within the first 30 days was 4.3 months, compared 
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to 11-month OS of other patients (HR 2.30, 95% CI: 
1.27–4.16, P=0.006). Among them, 31 individuals receiving 
steroids for the clinical management of irAEs did not show 
significant differences in terms of OS as compared to those 
without irAEs (OS: 16.1 vs. 10.5 months; 95% CI: 8.6–12.2, 
P=0.50) (33).
Fucà et al. conducted another retrospective analysis on 
a total of 151 patients diagnosed with metastatic NSCLC 
undergoing CPIs treatment. In this study, steroid exposure 
was defined as the ≥10 mg-prednisone administration in 
at least one of the 28 days preceding the CPIs’ treatment 
initiation. The 35 steroid-exposed patients (23% of the 
overall population) showed significantly worse PFS (HR 
1.80, P=0.003) and OS (HR 2.60, P<0.001) than the non-
exposed cohort (34).
Numerous subsequent reports, which were published as 
abstracts in several congresses, appear to be aligned with the 
above-mentioned evidence, overall showing a detrimental 
effect of a concomitant use of steroids at baseline on CPIs’ 
efficacy and patients’ survival (Table 1) (35-38).
Of note the only report considering corticosteroids 
administration during CPIs’ therapy exclusively devoted 
to the clinical management of irAEs showed no significant 
difference in terms of OS (14.5 vs. 30.0 months, P=0.30; 
HR 0.69), PFS (7.8 vs. 9.6 months, P=0.11; HR 0.65) and 
ORR (46% vs. 41%; P=0.64) between steroids and non-
steroids group, respectively (39).
Interestingly, two most recent studies, analyzed the 
effects of corticosteroids on CPIs’ treatment efficacy 
considering the reason of their administration by splitting 
cancer-related palliative indications (brain metastases, 
dyspnea, bone metastases, anorexia) from cancer-unrelated 
indications (irAEs, COPD exacerbation, AID, pain, 
chemotherapy or iodinate contrast prophylaxis etc.).
In the retrospective study by Ricciuti et al., the poorest 
survival outcome likely applies to the subgroup of patients 
who received 10 mg-prednisone for palliative purposes. 
They identified a total of 650 CPI-treated, advanced 
NSCLC patients, of whom 93 received prednisone ≥10 mg 
or its equivalent within 24 hours of CPI initiation. Among 
them, 66 patients were on steroids treatment for cancer-
related palliative symptoms, including symptomatic brain 
metastases (57.6%), dyspnea (18.2%), bone metastases 
(16.7%), and anorexia (7.6%), whilst 27 patients for cancer 
unrelated conditions. Patients who received ≥10 mg of 
prednisone for palliative indications showed significantly 
worse survival outcomes compared to those receiving 
≥10 mg of prednisone for cancer unrelated indications 
or lower dose of steroids (PFS: 1.4 vs. 4.6 vs. 3.4 months, 
P=0.001; OS: 2.2 vs. 10.7 vs. 11.2 months, P=0.001). 
Conversely no survival differences were observed between 
patients receiving ≥10 mg prednisone for non-cancer 
related indications and those on lower dose of steroids, 
both in terms of PFS (4.6 vs. 3.4 months; HR 0.77; 95% CI: 
0.50–1.19; P=0.24) and OS (10.7 vs. 11.2 months; HR 0.93; 
95% CI: 0.59–1.48; P=0.77) (40).
Similarly, De Giglio et al. performed a retrospective 
analysis on a total of 49 NSCLC patients who received early 
steroids therapy at Gustave Roussy Cancer Institute, whose 
39 patients for cancer-related symptoms, including dyspnea 
(50%), brain metastases (15.8%), pain (7.9%), superior vena 
cava syndrome (7.9%), fatigue (5.3%), others (13.1%), and 
the remaining 10 patients for other causes, like the clinical 
management of irAEs (54.6%). Patients receiving steroids 
for cancer-related symptoms had significantly poorer 
outcomes with early steroids introduction reported to be an 
independent prognostic factor for both poor PFS (HR 3.04; 
95% CI: 1.38–6.66; P=0.006) and OS (HR 1.21; 95% CI: 
0.53–2.8; P<0.0001). No differences were observed between 
the group of patients subjected to steroids therapy for other 
indications [PFS 2.7 months (1.21–NR); OS 13.4 months 
(4.30–NR)] and the group of steroids-naïve patients [PFS 
2.6 months (2.20–3.94); OS 13.8 months (11.4–18)] (41).
Critical discussion
Corticosteroids are immunomodulatory agents regulating 
gene expressions and signaling pathways through both 
genomic and non-genomic mechanisms (21,42), thus 
exerting their dose-dependent immunosuppressive 
action on T cells, which constitute the effector arm of 
immunotherapy.
In the antitumor response, PD-1 exerts its inhibitory effects 
mainly at local level, in the tumor microenvironment (43) 
thus PD-1/PD-L1 CPIs aim to reverse the exhaustion 
of pre-existing tumor-residing T-cells, by restoring their 
effector functions, in order to produce tumor regression 
(44-46).
Nonetheless, it has not been clarified yet whether 
steroids administration block the differentiation of 
stimulated T cells or deplete already differentiated tumor-
reactive lymphocytes. Therefore, it remains unclear how 
steroids alter the adaptive anti-tumor immunity and 
whether steroids effects on immune response may vary 
according to their dosage, administration time-point/
duration, as well as on the basis of primary tumor location.
2881Translational Lung Cancer Research, Vol 10, No 6 June 2021
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Although initial real-world clinical data (32) suggested 
a significant association between the dose of steroids 
administration and the therapeutic effects of CPIs, recent 
evidence (34,40) revealed that the immunosuppressive effect 
of corticosteroids is more timely- than dose-dependent. 
Several preclinical studies explored whether the 
dexamethasone administration timing may significantly 
affect immunotherapeutic treatment efficacy (47,48). 
The results of these studies revealed that early steroid 
administration only, through the reduction of the T 
lymphocyte peripheral pool, might compromise the early 
adaptive immune response enhanced by anti-PD-1 therapy, 
thus impairing the clinical efficacy of these agents. 
Most of the studies exploring the implications of steroids 
administration in NSCLC patients under CPIs’ treatment, 
which are being considered in this instance, appear to 
support this item. Particularly, Fucà et al. provides a 
potential biological explanation to the early corticosteroid 
use negative effects on the antitumor immune response 
elicited by CPI therapy (34), showing as white blood 
count (WBC), absolute neutrophil count (ANC) and 
derived neutrophil to lymphocyte ratio (dNLR), were 
significantly higher in steroids-treated patients than the 
non-exposed cohort, both at baseline and at 4/6 weeks after 
CPI initiation. Interestingly a high percentage of steroids-
treated patients showed a NLR ≥5 (OR 5.40, 95% CI: 1.95–
16.70, P<0.001) and a dNLR ≥3 (OR 10.32, 95% CI: 3.43–
39.43, P<0.001) as compared to the control cohort, thus 
suggesting as the dynamic modulation of peripheral blood 
immune cells during the treatment course might mediate 
immunotherapy resistance induced by corticosteroid 
administration. 
Nonetheless, the relevance of the negative prognostic 
effect of steroids should be cautiously considered when they 
are used in NSCLC patients with metastatic disease. Indeed, 
when steroids administration was stratified and analyzed 
separately according to the specific clinical indication, 
the concomitant use of corticosteroids for non-palliative 
purposes did not appear to significantly affect CPIs-treated 
patients’ survival anymore, regardless of their dose of 
administration (40,41). Although limited by a retrospective 
design, low number and heterogeneity of included 
patients, the results of most recent studies suggested that 
the negative impact of steroids on CPIs’ efficacy may 
be mainly ascribed to the worse prognosis of patients 
candidate to early palliative cure for their symptomatic 
disease. Moreover, subgroup analysis suggested that steroid-
treated patients were commonly characterized by negative 
prognostic clinical features, such as ECOG-PS ≥2, baseline 
brain metastases, and higher number of metastatic sites 
(32-34), thus confirming the predominant prognostic role 
of steroids at CPIs’ therapy initiation. 
On the other hand, once anti-tumor immunity has 
been initiated, the negative impact of corticosteroids on 
immune function is markedly reduced (47). In line with 
this hypothesis, neither steroid administration for irAEs 
treatment nor the short-course of steroid use within 
premedication protocol for chemo-immunotherapy 
combinations (9-11) significantly influenced the survival 
outcomes of NSCLC patients (28,29,31). 
Finally, preclinical studies suggested that blocking 
CTLA-4,  but  not  PD-1,  part ia l ly  rescued T-cel l 
proliferation in the presence of dexamethasone in vitro (49). 
This type of evidence is likely related to the different 
effect of CTLA-4 blockade, usually acting on less 
differentiated and more dexamethasone-sensitive T-cells 
subsets, suggesting a different effect of steroids on anti-
CTLA-4 and anti-PD-1/PD-L1 agents activity. Different 
studies have previously found that corticosteroids did not 
negatively impact OS of cancer patients on immunotherapy 
involving CTLA-4 blockade (28,50-54). Although none of 
these studies was specifically powered to address the impact 
of steroids on CPIs’ efficacy, these evidences could partially 
reflect the anti-CTLA-4 specific capability of counteracting 
steroids effects. Conversely other clinical experiences 
suggested a potential detrimental effect of early steroids 
administration on the ipilimumab anti-tumor activity, 
requiring further investigation in dedicated studies (55). 
Moving from bench to bedside, it will be interesting 
to see whether and how steroids use could affect the anti-
CTLA-4 plus anti-PD-1 blockade efficacy, since this kind 
of combination has been recently entered as additional first 
line treatment option for patients with metastatic, non-
oncogene addicted NSCLC, at least in the United States. 
Autoimmune diseases 
Clinical evidences
Among patients diagnosed with lung cancer, a percentage 
ranging from 14% to 25% is likely to have a concomitant 
AID (56). Female patients, elderly and early stage have 
higher chances of being part of this overlapping group 
(P<0.001). Moreover, it has been shown that some 
autoimmune disorders such as rheumatoid arthritis (RA), 
contribute to the onset of neoplasms. Indeed, subjects 
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affected by RA present a double risk of developing lung 
cancer as compared to the healthy population, with cigarette 
smoking and lung chronic inflammation underlying this 
clinical association (57).
The concerns about exacerbations of pre-existing 
AID as well as the major susceptibility to severe irAEs 
as consequence of the reactivation of immune response 
induced by the checkpoint blockade led to the exclusion of 
patients with autoimmune disorders from the randomized 
phase III clinical trials leading to the approval of CPIs’ 
therapy in lung cancer patients. However, different real 
word studies and retrospective series evaluated the potential 
clinical implications CPIs therapy in cancer patients with 
AIDs (Table 2). 
A study published in 2018, including 172,285 patients 
with a lung cancer diagnosis performed between 1992 and 
2009, showed that, in absence of CPIs’ administration, 
the presence of a concomitant AIDs did not influence the 
treatment pattern and was not associated with an increased 
mortality (63).
In a prospective study based on REISAMIC (Registry of 
Severe Adverse events of Immunomodulating monoclonal 
antibodies in oncology), the association between pre-
existing AIDs and irAEs free survival, OS and best ORR 
was investigated, with 45 out of 397 enrolled cancer 
patients harboring a concomitant AIDs diagnosis. The 
most frequent AIDs were vitiligo (n=17), psoriasis (n=12), 
autoimmune thyroiditis (n=7), Sjögren’s syndrome (n=4) 
and RA (N=2). The incidence of irAEs in patients with 
autoimmune pathologies was 44.4% compared to 23.8% 
of the remaining population. IrAEs median free survival 
was seen to be lower in patients with previous AIDs (5.4 
months) compared to the control cohort (13 months). 
However, no OS and ORR differences were observed 
between the two groups (58). The study did not consider 
grade 1 immune-mediated toxicities in order to avoid 
detection bias, since the diagnose of mild immune-mediated 
toxicities is easier in patients with previous autoimmune 
disorders. On the other hand, this may have led to an 
underestimation of the incidence of irAEs. Furthermore, 
the authors didn’t differentiate between clinically active and 
inactive AID at the time of anti PD-1 blockade initiation. 
In another multicenter retrospective study published 
in 2019, among 751 stage IV cancer patients, the most 
represented tumor was NSCLC (65.5%) followed by 
melanoma and kidney cancer. Seventy out of 751 had a 
pre-existing inactive AID, i.e., not being treated at the 
time of immunotherapy initiation, and 15 presented 
an active disease that required the administration of 
immunosuppressive drugs (corticosteroids in 73.3% of 
cases). The incidence of any grade irAEs in the population 
with previous AIDs was 65.9% (95% CI: 49.7–85.5%), 
compared to 39.9% (95% CI: 35.2–45.0%) in patients 
without AIDs. However, not significant differences in 
the incidence of grade 3–4 irAEs [9.4% (95% CI: 4.1–
18.5%) vs. 8.8% (95% CI: 6.7–11.4%)], ORR (38.1% 
inactive/50% active AID vs. 35.3% no AID), median PFS 
(14.4 inactive/6.8 months active AIDs vs. 8 months no AID) 
and median OS (15.7 inactive/9.8 months active AID vs. 
16.5 months no AID) were reported. Focusing on specific 
subgroups, patients with active AIDs seemed to have higher 
ORR (50%) compared with patients with inactive AIDs 
(38.1%) and those without (35.3%) AIDs. Conversely, a 
not significant trend toward a worse median PFS has been 
observed in patients with active (6.8 months) vs. inactive 
(14.4 months) AIDs (58). Similarly, worse median OS has 
been reported in patients with active (9.8 months) compared 
to inactive (15.7 months) or no (16.5 months) AIDs, likely 
due to the impact of the disease on life expectancy, being 
aware that the transient interruptions of immunotherapy 
due to toxicity should not affect OS (26,59).
Interestingly, patients with ECOG-PS >2 seemed to have 
a lower incidence of irAEs, likely due to their poor general 
conditions, which may have impaired the reactivity of their 
immune system (59).
Another study published in 2018 in JCO, analyzed a 
total of 56 patients diagnosed with NSCLC and AIDs 
undergoing immunotherapy. About 55% of patients 
developed irAEs (38%) and/or AIDs’ exacerbation (23%). 
The irAEs were mostly of mild grade (74%) but in 26% of 
cases, a severe irAE has been reported. Half of them did not 
require immunosuppressive therapy for symptom control 
and, the majority of the remaining patients were treated 
with only corticosteroids. As regards AIDs’ exacerbations, 
they were G1–G2 in 87% of cases, and G3 in the remaining 
13% of cases, while no G4 events occurred. Importantly 
exacerbations were more frequent in patients with 
symptomatic versus non-symptomatic AIDs (50% vs. 18%) 
at the time of immunotherapy initiation. Furthermore, no 
difference in flares incidence was found between patients 
assuming an immunosuppressive drug at baseline and those 
who did not, while in the 5% of cases a concomitance of 
AIDs and irAEs flares has been described.
In this study, the overall percentage of G3–G4 irAEs 
was found to be 11%, in line with that (7–15%) emerging 
from the CPIs registration studies, which did not include 
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AIDs affected patients. However, the rate of treatment 
discontinuation due to immune related toxicity was 
significantly higher (14% vs. 3–8%) (60).
A poster presented at ASCO 2019 by Sean Khozin 
showed the results of a retrospective observational cohort 
study including 2,425 patients with stage III–IV NSCLC, 
who received at least one dose of CPI therapy. A diagnosis 
of AID was reported in 22% of patients (n=538), whose 
median survival was similar to that observed in the 
remaining population not affected by AIDs. Unlike the 
previous evidence, the results of this study did not show 
increased risk of developing irAEs in the AIDs-affected 
subgroup (64).
Similarly, a recent retrospective study including 29 CPIs’ 
treated patients with advanced lung cancer (adenocarcinoma 
59%, squamous cell carcinoma 34%, small cell cancer 7%, 
undifferentiated 3%), showed a not-increased incidence 
of irAEs in patients with AIDs compared to the control 
population. Furthermore, no significant survival differences 
have been observed according to both irAE occurrence 
and baseline immunomodulatory therapy (65). However, 
another retrospective study including 112 cancer patients 
with AIDs treated with immunotherapy (anti-PD-1/PD-
L1 83%, anti-CTLA-4 13%, combination 3%), showed a 
reduced PFS in patients who developed immunotoxicity 
(irAEs or AID flares), as compared to the control cohort (HR 
1.97, P=0.032) (61).
An international multicenter retrospective study 
analyzed 102 cancer patients with a concomitant diagnosis 
of inflammatory bowel disease (IBD) who were treated 
with immunotherapeutic drugs. Among these, 49 patients 
suffered from Crohn’s disease, 49 from ulcerative colitis and 
4 from unclassified inflammatory disease, while the control 
group consisted of 11,377 cancer patients with no IBD 
receiving immunotherapy. The most represented tumor 
was melanoma (44%) followed by NSCLC (23%) and 
gastrointestinal (GI) tumors (17%), with 83% of patients 
receiving an anti PD-1/PD-L1 agent. Among the 102 
analyzed patients, 42 (41%) presented a GI side effect, with 
a median incidence of 62 days from the treatment initiation, 
and 23 of them discontinued immunotherapy. Forty-one 
patients developed diarrhea, of grade 3–4 in about half 
of cases, and 29% required the administration of non-
steroidal immunosuppressive drugs, such as Infliximab and 
Vedolizumab. Due to the side effects, 32 patients underwent 
endoscopic investigation leading to the detection of mucosal 
ulceration in 38% and of non-ulcerative inflammation 
in 44% of cases. A total of 4 patients underwent a colic 
perforation. In the control group, the incidence of GI side 
effects was significantly lower (11%). Of the 42 patients 
who developed toxicities, 15 presented a second episode 
during the follow-up period. Patients who had active IBD 
in the three months prior to immunotherapy initiation 
experienced higher grade diarrhea than patients with 
inactive IBD. No difference in severity of GI adverse effects 
was observed between patients who were being treated for 
IBD at the beginning of immunotherapy and those who 
were not. The tumor response to CPIs’ therapy was similar 
between patients affected by IBD and those who did not, 
suggesting the effectiveness of immunotherapy treatment 
even in this particular population (62).
Critical discussion
The major concerns about the use of immunotherapy in 
NSCLC patients with pre-existing AIDs was related to an 
increased risk of developing serious irAEs and a flare-up of 
their baseline pathological conditions, as compared to the 
general cancer population (4-6). 
The occurrence of irAEs has been reported to be 
higher in patients with pre-existing AIDs compared to 
the control population, however the majority of irAEs 
are mild and well-controlled by corticosteroids use, with 
a limited number of patients requiring non-steroidal 
immunosuppressive drugs for high grade toxicities (60,61). 
A transient discontinuation of CPIs’ therapy (59,61,65) 
due to irAEs occurrence may be required, but, according 
to available evidence, no significant increased risk of high-
grade irAEs leading to permanent suspension of CPIs’ 
treatment has been reported. Particularly the percentage 
of NSCLC patients experiencing high-grade irAEs and 
CPIs’ treatment discontinuation were 11% and 14%, 
respectively, thus very similar to those reported in clinical 
trials not including AIDs population. Conversely the 
risk of developing AID flare seems to be related to the 
presence of AID symptoms at the time of CPIs initiation 
with a mild prevalence among patients diagnosed with 
rheumatologic AID (60). Therefore, particular attention 
should be paid to the clinical management of patients with 
active and symptomatic preexisting AIDs who are candidate 
to receiving CPIs’ therapy. As regards the immunotherapy 
effectiveness in this special population, the available 
evidence suggested a similar activity of CPIs’ therapy in 
NSCLC patients with or without AIDs, with worse OS 
limited to symptomatic AIDs cases. 
In the majority of the aforementioned studies (Table 2) 
2885Translational Lung Cancer Research, Vol 10, No 6 June 2021
© Translational Lung Cancer Research. All rights reserved.   Transl Lung Cancer Res 2021;10(6):2876-2889 | http://dx.doi.org/10.21037/tlcr-20-635
CPIs have been administered in pre-treated patients, thus 
leading to a potential underestimation of the real incidence 
of irAEs in this special population considering that the 
long lasting and widespread use of immunotherapy in 
first-line may be associated to higher risk of developing 
irAEs, especially in those patients with pre-existing AIDs. 
Similarly, the survival outcomes reported in these studies 
(Table 2) should be carefully interpreted as they reflect the 
health status of cancer patients who had previously received 
other cancer treatments, whose influence on immune 
reactivity is not known and established yet. 
Comforting data about the use of immunotherapy 
also comes from studies conducted on patients with IBD, 
to whom the treatment benefits seem to outweigh the 
risks. However, patients with active IBD at the time of 
immunotherapy initiation, seem to have higher risk of 
developing severe immune mediated GI adverse events 
and, therefore require to be early identified and adequately 
managed and treated, if necessary. In this regard, the early 
introduction of immunosuppressive drugs such as Infliximab 
and Vedolizumab has been indeed associated to better 
survival outcomes, especially in those patients with a severe 
endoscopic presentation (62).
According to Haanen et al., patients with autoimmune 
disorders and cancer requiring immunotherapy could 
benefit from a 2-step approach with personalized therapy 
depending on the autoimmune pathology itself. The 
suggested algorithm foresees a first phase lasting 1 month, 
whose objective is to control the autoimmune pathology 
with specific immunosuppressive drugs, limiting the use 
and dose of corticosteroids, and a second phase in which the 
immunotherapeutic drug may be introduced. The periodic 
follow-up aims to evaluate any chemical alterations in the 
laboratory and clinic to detect any exacerbations at an early 
stage and intervene with specific targeted therapies (66).
Finally, a 2019 Japanese study investigated the possible 
influence of antinuclear antibody (ANA) positivity on 
the incidence of irAEs. The authors demonstrated that 
ANA+ patients did not present a higher risk of developing 
irAEs compared with negative patients but showed shorter 
PFS and OS. This is likely due to the underlying chronic 
inflammatory status, which is a known factor influencing 
carcinogenesis (67,68). Furthermore, 10 out of 18 baseline 
ANA+ patients recruited in the study were monitored for 
ANA titer during CPIs’ treatment, with 3 of them showing 
an increase of this value and a subsequent development of 
irAEs. Although very preliminary, these data suggested that 
a dynamic monitoring of ANA value could play a potential 
role in the measurement of patient immunoreactivity, as 
predictive factor for the development of irAEs (67).
Ongoing prospective studies are currently investigating 
the efficacy and safety profile of immunotherapy in NSCLC 
diagnosed with AIDs (NCT03656627, NCT03816345).
Conclusions 
The real impact of both concomitant steroids therapy and 
AIDs on immunotherapy efficacy/tolerability in NSCLC 
patients remains an actual and controversial topic requiring 
prospective investigation, in order to develop standardized 
selection criteria and shared recommendations for their 
clinical management. In the current scenario, characterized 
by limited knowledge and lack of dedicated guidelines, 
an international panel of experts from the International 
Association for the Study of Lung Cancer (IASLC) have 
recently provided practical suggestions which may guide 
physicians in their current practice (69). Therefore, 
according to the IASLC panel: “not all patients with metastatic 
NSCLC receiving concomitant steroids treatment should be 
excluded from CPIs therapy and discontinuation of steroids is not 
always required at the time of CPIs initiation”. Similarly, “CPIs’ 
therapy may be offered to NSCLC patients affected by non-
life-threatening and asymptomatic AIDs”. Finally, a clinical 
decision on each individual patient is currently suggested 
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